Phaseline

Targets › CALR

CALR (Calreticulin): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Mar 2027.

Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle. This lectin interacts transiently with almost all of the monoglucosylated glycoproteins that are synthesized in the ER. Interacts with the DNA-binding domain of NR3C1 and mediates its nuclear export. (UniProt, P27797)

Open in Phaseline: the race on CALR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Marina KremyanskayaMutant-CALR peptide vaccine
Mutant CALR peptide-based therapeutic vaccine
CALRPhase 1MyelofibrosisMar 2027
Johnson & Johnson (Janssen)JNJ-88549968
CALR-targeting therapy for calreticulin-mutated myeloproliferative neoplasms
CALRPhase 1NeoplasmsJun 2027

Conditions

Myelofibrosis (1) Neoplasms (1)

Modalities

mixed (1), small molecule (1)

Companies

Marina Kremyanskaya (1) Johnson & Johnson (Janssen) (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.